Our Next Show
Friday, August 28, 2 pm PDT, 3 pm MDT, 4 pm CDT, 5 pm EDT
Call In by Phone to Listen Live: (347) 637-2631 or
We’ve learned that c-MYC is the most common translocation in multiple myeloma – and that it becomes more abundant as the myeloma gets more aggressive. As a very desirable target, learn what Dr. Jay Bradner is doing to target this most common translocation and his work to study pathways that regulate myeloma using chemical biology. As he studies genetic alterations that cause myeloma, he seeks to reprogram the cell’s fundamental identity and subvert the aggressive behavior of myeloma cells. Dr. Bradner’s work to control a cell’s identity is an approach to deliver the heaviest impact for the widest set of myeloma patients possible. Dr. Bradner directs a laboratory that studies transcription factors, chromatin modifying enzymes and histone binding modules.
Dr. James (Jay) Bradner is a Staff Physician in the Division of Hematologic Malignancies at Dana-Farber Cancer Institute as well as an Associate Professor in Medicine at Harvard Medical School. He is also Associate Director, Center for the Sciences of Therapeutics, at the Broad Institute. Dr. Bradner is Scientific founder of Tensha Therapeutics and Syros Pharmaceuticals, is on a lengthy number of Harvard, Dana Farber and Brigham & Women’s committees and is on the National Board of Directors for the LLS and additional LLS committees. He is the Development Committee Chair for ASH and is on review boards for the MMRF, the Samuel Waxman Research Foundation, the Leukemia Research Foundation, the Leukemia and Lymphoma Society and the Doris Duke Charitable Foundation. Dr. Bradner is an ad-hoc reviewer for over 15 major hematology publications and has received numerous awards including the ASH Scholar Award, Damon Runyon Cancer Research Foundation Innovation Award and the Nakada Award from the University of Pittsburgh. Dr. Bradner leads the very large Bradner Lab which studies gene regulatory pathways using the newer discipline of chemical biology.
New, Comprehensive Site for the Myeloma Community
A myeloma diagnosis is overwhelming and the learning curve is steep.
The myelomacrowd.org website was created by patients for patients and offers a comprehensive and current view of Myeloma— all in one place.
Together as patients and caregivers we can make more informed decisions about our care that will drive better outcomes for us all. Register and join the Myeloma Crowd today!
Our Most Recent Episode
Detecting myeloma relapse early – The new Hevylite® test can help with Dr. Stephen Harding of The Binding Site
Dr. Stephen Harding The Binding Site Group Interview Date: July 18, 2014 Summary No myeloma patient wants to hear the word “relapse,” but how can we identify it early so it can be treated? A new FDA approved test called Hevylite® is now available that can pick up myeloma growth before it is seen in […]
Our Previous Episodes
What's new in MGUS? Very interesting ASCO findings and the diagnostics you need to have as an MGUS patient with Dr. Brendan Weiss, MD
The hopeful discovery of an engineered measles virus for myeloma treatment with Dr. Stephen Russell, MD, PhD
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
A compelling European approach in myeloma care: Collaboration, Referrals and Established Guidelines with Dr. Pieter Sonneveld, MD, PhD, Erasmus MC
Myeloma is not a single disease: The illuminating discovery and implications for care with Dr. Michael Kuehl, MD, PhD of the NCI
Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants
Three myeloma themes with Dr. Robert Z. Orlowski of MD Anderson Cancer Center:Immunotherapy, making transplant better and using new small molecules for more convenient myeloma care
Dr. Leif Bergsagel, MD of the Mayo Clinic shares the impact of the MYC translocation in myeloma progression and relapse and a new target that boosts immunity while impacting myeloma cells
Genes that drive myeloma growth and why new discoveries of myeloma's complexities are hopeful with Dr. Jens Lohr, MD of The Broad Institute and Dana Farber Cancer Institute
Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission
Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the "Valley of Death"
Our Next Show: How does a drug begin as an idea and become an actual myeloma therapy in the clinic? Dr. Craig Crews, Crews Laboratory at Yale University discusses his discovery and development of carfilzomib (Kyprolis)
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases
Dr. Philip McCarthy of Roswell Park Cancer Institute on transplants: best induction therapies, best approaches for high risk and how patients can recover faster
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation) to selectively target only active myeloma cells using the common CD38 protein
Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
Shutting down myeloma growth by changing the soil where it grows with Dr. Noopur Raje of Massachusetts General Hospital Cancer Center
What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.
Are you confused by your myeloma labs? Dr. Michael Misialek says your pathologist is ready and willing to help decipher the results.
The path to personalized medicine: Dr. Gareth Morgan describes his work to subdivide myeloma into actionable types, target specific genes and pathways, and study the impact of the bone marrow environment
Dr. Rodger Tiedemann discusses why myeloma persistently returns and his work to strike at the root of the disease by targeting earlier stage progenitor cells
Find a multiple myeloma specialist near you. We’ve moved this directory to the www.myelomacrowd.org site.